CI
ALT icon

Carroll Investors’s Altimmune ALT Stock Holding History

Carroll Investors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-272
Closed -$2K – 171
2021
Q4 		$2K Buy
+272
New +$2.89K ﹤0.01% 177

Other funds holding ALT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Carroll Investors's ALT Position: Q1 2022 in Review

Carroll Investors sold out of Altimmune (ALT) in Q1 2022, closing a stake of 272 shares — an estimated $2K sold.

Carroll Investors first reported a position in ALT in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 103 funds tracked by Wall St. Rank hold ALT as of Q1 2022.

  • Carroll Investors reported no remaining Altimmune position as of Q1 2022 after selling out during the quarter.
  • Carroll Investors sold 272 Altimmune shares in Q1 2022, an estimated $2K.
  • Carroll Investors first reported a position in Altimmune in Q4 2021 and held it in 1 quarter.
  • Carroll Investors's Altimmune position peaked at $2K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Altimmune as of Q1 2022.

Based on Carroll Investors's 13F filing for Q1 2022, filed 28 Apr 2022.